We are live on ! Find out more

Geron

GERN

Market cap $608M

0.9462 USD

-0.0223

2.3%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

0.9437

-0.0025

0.26%

1 day

-2.3%

5 days

-17.72%

1 month

-23.69%

3 months

-32.41%

6 months

-37.34%

Year to date

-28.32%

1 year

-23.07%

5 years

-38.56%

10 years

-48.85%

About: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Employees: 258

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 72.7%

Negative 9.1%

Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth

Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.

Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth

Geron discontinues late-stage trial of blood cancer drug

Geron said on ‌Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.

Geron discontinues late-stage trial of blood cancer drug

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Committee (DMC).

$Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis$

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective October 16, 2026, it granted stock options to purchase an aggregate of 570,000 shares of common stock to three newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the prolif.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™